U.S. markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
651.88-1.30 (-0.20%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close653.18
Open649.17
Bid635.19 x 1200
Ask653.97 x 900
Day's Range643.29 - 653.00
52 Week Range441.00 - 686.62
Volume762,045
Avg. Volume779,923
Market Cap69.722B
Beta (5Y Monthly)0.16
PE Ratio (TTM)11.77
EPS (TTM)55.38
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est677.04
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
16% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Regeneron Pharmaceuticals, Inc.
    Analyst Report: Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.
    Rating
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more